



## **Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference in New York City on Tuesday, February 9th**

IRVINE, Calif., Feb 05, 2010 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced today that Rajesh C. Shrotriya MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, will provide an overview of the Company's business strategy at the 2010 BIO CEO Investor Conference on Tuesday, February 9, 2010, at 11:30am Eastern Time. The conference is being held at the Waldorf Astoria Hotel in New York City. The Spectrum Pharmaceutical presentation will be given in the Basildon room.

The live webcast of Spectrum's corporate presentation will be available at <http://www.sppirx.com>.

In addition, at 10:30am Eastern Time on Tuesday, February 9<sup>th</sup>, Dr. Shrotriya will be a panelist on the topic of "*Alternative Financing Strategies: PIPEs, Follow-Ons, and Private Placements.*" The panel will be in the Jade room of the Waldorf Astoria Hotel.

### **About Spectrum Pharmaceuticals**

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The Company's strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. In addition to building an efficient in-house clinical research organization with regulatory and data management capabilities, the Company has established a commercial infrastructure for its drug portfolio. The Company markets two oncology drugs, FUSILEV<sup>(R)</sup> and ZEVALIN<sup>(R)</sup> and has two drugs in late stage development, apaziquone (EOquin<sup>(R)</sup>) and belinostat, along with a diverse pipeline. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company's website at [www.sppirx.com](http://www.sppirx.com).

*Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.*

SPECTRUM PHARMACEUTICALS, INC. (R), ZEVALIN(R), and FUSILEV(R) are registered trademarks of Spectrum, EOquin(R) is a registered trademark of Allergan Inc., TURNING INSIGHTS INTO HOPE(TM) and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

© 2010 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

SOURCE: Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.  
Paul Arndt  
Senior Manager, Investor Relations

949-788-6700 x216

Copyright Business Wire 2010